- Home
- WT vs SUPN Comparison
WT vs SUPN Comparison
Compare WT & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WT | SUPN |
|---|---|---|
| Founded | 1985 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 2011 | 2010 |
Fundamental Metrics
Financial Performance| Metric | WT | SUPN |
|---|---|---|
| Price | $22.57 | $47.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $17.67 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 2.6M | 909.0K |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | ★ 127.27 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $493,753,000.00 | $392,755,000.00 |
| Revenue This Year | $35.04 | $22.70 |
| Revenue Next Year | $8.68 | $19.14 |
| P/E Ratio | $157.14 | ★ N/A |
| Revenue Growth | ★ 15.43 | N/A |
| 52 Week Low | $10.69 | $41.76 |
| 52 Week High | $23.15 | $59.68 |
Technical Indicators
Market Signals| Indicator | WT | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 66.20 | 51.05 |
| Support Level | $16.06 | $43.27 |
| Resistance Level | $23.15 | $47.55 |
| Average True Range (ATR) | 0.96 | 2.50 |
| MACD | 0.20 | 0.08 |
| Stochastic Oscillator | 86.69 | 43.60 |
Price Performance
Historical ComparisonAbout WT WisdomTree Inc.
WisdomTree Inc is a financial innovator, offering a diverse suite of Exchange-traded products (ETPs), models and solutions, private market investments and digital asset-related products. It also offers digital products and services related to tokenized real world assets and stablecoins, including tokenized mutual funds (Digital Funds), as well as its institutional platform, WisdomTree Connect, and blockchain-native digital wallet, WisdomTree Prime. The company's products are distributed across various asset management industry channels, including banks, brokerage firms, registered investment advisers, institutional investors, private wealth managers and online brokers. The majority of the company's revenue is generated from advisory fees earned from ETPs.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.